

Contains
 Exact Match
 Begins With
 Name
 Code
 Property
 Relationship

Source: [Advanced Search](#)

NCIm Version: 201808 (Browser Version 2.9, using LexEVS 6.5.1)

[Home](#) | [NCIt Hierarchy](#) | [Sources](#) | [Help](#) | [Visited Concepts](#)

Anti-KIR3DL2 Monoclonal Antibody IPH4102 (CUI CL503845)

[Suggest changes to this concept](#)
[Add to Cart](#)
[Terms & Properties](#) | [Synonym Details](#) | [Relationships](#) | [By Source](#) | [View All](#)

Terms & Properties

Concept Unique Identifier (CUI): CL503845

NCI Thesaurus Code: C124999 ([see NCI Thesaurus info](#))

Semantic Type: Pharmacologic Substance

Semantic Type: Amino Acid, Peptide, or Protein

Semantic Type: Immunologic Factor

NCIt Definition: A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-KIR3DL2 monoclonal antibody IPH4102 binds to KIR3DL2 expressed on certain tumor cells. This recruits natural killer (NK) cells and leads to lysis of KIR3DL2-expressing tumor cells. In addition, IPH4102 induces antibody-dependent cellular cytotoxicity (ADCC), thereby further eliminating tumor cells. KIR3DL2, a tumor-associated antigen (TAA) and inhibitory receptor of the KIR family, is specifically expressed in most subtypes of cutaneous T-cell lymphomas (CTCL) and expressed only on a fraction of normal NK cells.

PDQ Definition: A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-KIR3DL2 monoclonal antibody IPH4102 binds to KIR3DL2 expressed on certain tumor cells. This recruits natural killer (NK) cells and leads to lysis of KIR3DL2-expressing tumor cells. In addition, IPH4102 induces antibody-dependent cellular cytotoxicity (ADCC), thereby further eliminating tumor cells. KIR3DL2, a tumor-associated antigen (TAA) and inhibitory receptor of the KIR family, is specifically expressed in most subtypes of cutaneous T-cell lymphomas (CTCL) and expressed only on a fraction of normal NK cells. Check for [active clinical trials](#) using this agent. ([NCI Thesaurus](#))

Synonyms & Abbreviations: ([see Synonym Details](#))

Anti-KIR3DL2 mAb IPH4102
 Anti-KIR3DL2 Monoclonal Antibody IPH4102
 IPH-4102
 IPH4102

External Source Codes:

NCI Thesaurus Code	C124999 (see NCI Thesaurus info)
FDA UNII Code	N8O7MY0VNS
PDQ Closed Trial Search ID	777272
PDQ Open Trial Search ID	777272 (check for NCI PDQ open clinical trial info)

Other Properties: [?](#)

Name	Value	Source
Contributing_Source	CTRP	NCI
Contributing_Source	FDA	NCI
DATE_FIRST_PUBLISHED	2015-12-03	PDQ
DATE_LAST_MODIFIED	2016-01-22	PDQ
NCI_THESAURUS_CODE	C124999	PDQ
ORIG_STY	Drug/agent	PDQ

Additional Concept Data: (none)

URL to Bookmark: [https://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=CL503845](https://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI%20Metathesaurus&code=CL503845)